Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Filings indexed 324 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Regulatory Filings
2026-05-07 English
S-8 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Registration Form
2026-03-18 English
10-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Annual Report FY 2025
2026-03-17 English
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Regulatory Filings
2026-03-17 English
4 - MONTE ROSA THERAPEUTICS, INC. (0001826457) (Filer)
Director's Dealing
2026-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.